ClinicalTrials.gg
CompletedNCT06017609POWER-HFUpdated Sep 24, 2026

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

A Phase 2 interventional study of JTT-861 Capsules and Placebo Capsules in Chronic Heart Failure, sponsored by Akros Pharma Inc.. Completed at 75 sites in 6 countries. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
354th of 1,602
314 · median 66
Started
2023
with 101 others
Phase 2
227 of 2,159
26 open now
Registered
1,825th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 354th largest by enrollment of the 1,602 interventional ones that give a count, is one of 102 that started in 2023, is one of 227 in phase 2, and was the 1,825th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • JTT-861
  • Efficacy
  • Safety
  • Tolerability
  • Chronic Heart Failure
  • HFrEF
  • Heart Failure
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a clinical diagnosis of symptomatic heart failure (HF) ≥90 days prior to the Screening Visit;
  • Is in (NYHA) functional class II or III at the Screening Visit;
  • Is on stable, guideline-directed therapy for HF, consistent with American Heart Association (AHA), American College of Cardiology (ACC), Heart Failure Society of America (HFSA) or European Society of Cardiology (ESC) guidelines for ≥4 weeks prior to the Screening Visit (with at least half of maximal labeled dose of renin-angiotensin-aldosterone system (RAAS) inhibitors and β-blockers, if tolerated);
  • Has (LVEF) ≤35% at the Screening Visit;
  • Has a serum N-terminal pro b-type natriuretic peptide (NT-pro-BNP) level ≥600 pg/mL (or ≥900 pg/mL if the subject has atrial fibrillation or atrial flutter) at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Has a confirmed acute myocardial infarction (MI) (i.e., Type 1) or unstable angina within 90 days prior to the Screening Visit;
  • Has a history of coronary revascularization (percutaneous coronary intervention [PCI] and/or coronary artery bypass graft [CABG]) or other cardiovascular surgery within 90 days prior to the Screening Visit or planned cardiovascular surgery during the study through the Follow-up Visit);
  • Has started cardiac resynchronization therapy (CRT) within 90 days prior to the Screening Visit or has planned CRT during the study through the Follow-up Visit;
  • Has congenital heart disease, active myocarditis or constrictive pericarditis;
  • Has current acute decompensated HF requiring additional treatment with diuretics, vasodilators and/or inotropic medications at the Screening Visit;
  • Has clinically significant chronic renal insufficiency (i.e., estimated [eGFR] \<30 mL/min/1.73 m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation) at the Screening Visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    JTT-861 Dose 1

    JTT-861 Capsules Dose 1 orally once daily for 12 weeks

    Drug: JTT-861 Capsules

  • Experimental
    JTT-861 Dose 2

    JTT-861 Capsules Dose 2 orally once daily for 12 weeks

    Drug: JTT-861 Capsules

  • Experimental
    Placebo

    Placebo Capsules orally once daily for 12 weeks

    Drug: Placebo Capsules

Interventions

  • DrugJTT-861 Capsules

    Active drug capsules containing JTT-861

  • DrugPlacebo Capsules

    Placebo capsules matching in appearance to the active drug capsules

06

What researchers measure

Primary outcomes

  1. Change from baseline to end of treatment (EOT) in left ventricular ejection fraction (LVEF) as assessed by two-dimensional echocardiography (2D-echo)

    Time frame: 12 Weeks

  2. Change from baseline to EOT in left ventricular end-systolic volume (LVESV) index as assessed by 2D-echo

    Time frame: 12 Weeks

  3. Change from baseline to EOT in left ventricular end-diastolic volume (LVEDV) index as assessed by 2D-echo

    Time frame: 12 Weeks

  4. Change from baseline to EOT in left atrial volume (LAV) as assessed by 2D-echo

    Time frame: 12 Weeks

  5. Change from baseline to EOT in N-terminal pro b-type natriuretic peptide (NT-pro-BNP) values

    Time frame: 12 Weeks

  6. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baseline

    General Scoring Guideline: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent

    Time frame: 16 Weeks

  7. Number of subjects with treatment-emergent adverse events

    Time frame: Up to 16 Weeks

  8. Trough plasma concentrations of JTT-861

    Time frame: Weeks 4, 8 and 12

  9. Post-dose plasma concentrations of JTT-861

    Time frame: Weeks 2, 4 and 8

07

Study locations

75 sites
  • Arensia Exploratory Medicine Inc.
    Phoenix, Arizona 85015, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Med Research of Florida
    Miami, Florida 33186, United States
  • Pharma Medical Innovation, Inc.
    Miami Lakes, Florida 33014, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Affinity Health
    Park Ridge, Illinois 60068, United States
  • ASHA Clinical Research-Munster, LLC
    Hammond, Indiana 46324, United States
  • Monroe Research, LLC
    West Monroe, Louisiana 71291, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Profound Research LLC
    Farmington Hills, Michigan 48334, United States
  • NextStage Clinical Research - (Kansas City [01])
    Kansas City, Missouri 64114, United States
  • Laurelton Heart Specialist P.C.
    Rosedale, New York 11422, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Onsite Clinical Solutions, LLC
    Rock Hill, South Carolina 29732, United States
  • NextStage Clinical Research-Beaumont- (01)
    Beaumont, Texas 77702, United States
  • Cypress Heart and Vascular Center
    Cypress, Texas 77429, United States
  • NextStage Clinical Research-Port Arthur-(02)
    Port Arthur, Texas 77642, United States
  • Sherman Clinical Research
    Sherman, Texas 75092, United States
  • Waco Cardiology Associates - NextStage Clinical Research
    Waco, Texas 76712, United States
  • Ambulatory for Specialized Outpatient Medical Care in Cardiology Individual Practice- Dr. Elena Dotcheva EOOD
    Burgas, 8000, Bulgaria
  • Multiprofile Hospital for Active Treatment "Ivan Skenderov"
    Gotse Delchev, 2900, Bulgaria
  • Multiprofile Hospital For Active Treatment Ivan Skenderov EOOD
    Gotse Delchev, 2900, Bulgaria
  • University Multiprofile Hospital for Active Treatment Georgi Stranski, EAD
    Pleven, 5803, Bulgaria
  • Multiprofile Hospital For Active Treatment Heart and Brain EAD
    Pleven, 5804, Bulgaria
  • University Multiprofile Hospital For Active Treatment Saint Georgi EAD
    Plovdiv, 4002, Bulgaria
  • Acibadem City Clinic University Multiprofile Hospital For Active Treatment EOOD
    Sofia, 1415, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
    Sofia, 1527, Bulgaria
  • Diagnostic Consultative Center Convex EOOD
    Sofia, 1680, Bulgaria
  • University Multiprofile Hospital for Active Treatment. Sv Anna - Sofia AD
    Sofia, 1750, Bulgaria
  • MUDr. Libor Nechvatal s.r.o.
    Brno, 602 00, Czechia
  • Centrum pro zdraví, s.r.o.
    Brno, 603 00, Czechia
  • Vojenská nemocnice Brno
    Brno, 615 00, Czechia
  • Fakultní nemocnice Brno
    Brno, 625 00, Czechia
  • Edumed s.r.o.
    Broumov, 550 01, Czechia
  • Edumed s.r.o.
    Hradec Králové, 500 02, Czechia
  • Edumed s.r.o.
    Jaroměř, 551 01, Czechia
  • Edumed s.r.o.
    Náchod, 547 01, Czechia
  • Fakultní nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • American Heart of Poland S.A.
    Chrzanów, 32-500, Poland
  • American Heart of Poland S.A.
    Dąbrowa Górnicza, 41-300, Poland
  • Kardio Brynów Sp. z o.o.
    Katowice, 40-555, Poland
  • Centrum Rehabilitacji I Kardiologii Solutaris Prokopczuk Sp.j.
    Kędzierzyn-Koźle, 47-200, Poland
  • Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego
    Lodz, 91-347, Poland
  • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie
    Lublin, 20-090, Poland
  • Trialmed CRS Piotrków Trybunalski
    Piotrkow Trybunalski, 97-300, Poland
  • NZOZ "Pro Cordis" Sopockie Centrum Badań Kardiologicznych Paweł Miękus
    Sopot, 81-717, Poland
  • American Heart of Poland S.A.
    Tychy, 43-100, Poland
  • 4 Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej we Wrocławiu
    Wroclaw, 53-114, Poland
  • Thera Card S.R.L
    Brasov, 500102, Romania
  • Spitalul Clinic Judetean De Urgenta Brasov
    Brasov, 500326, Romania
  • Spitalul Clinic De Urgență Sf. Pantelimon București
    Bucharest, 021659, Romania
  • Spitalul Universitar de Urgență București
    Bucharest, 050098, Romania
  • Mat Cord Biomedica SRL
    Buzău, 120133, Romania
  • Angiocare S.R.L.
    Cluj-Napoca, 400015, Romania
  • Cardio Med SRL
    Craiova, 200513, Romania
  • Spitalul Clinic Județean de Urgență Craiova
    Craiova, 200642, Romania
  • Cardio Med SRL
    Târgu Mureş, 540124, Romania
  • CMI Dr. Podoleanu Cristian
    Târgu Mureş, 540143, Romania
  • Spitalul Clinic Municipal de Urgenţă Timişoara
    Timișoara, 300024, Romania
  • Spitalul Clinic Municipal de Urgenţă Timişoara
    Timișoara, 300079, Romania
  • Hospital Clínico Universitario de Santiago
    A Coruña, 15706, Spain
  • Hospital del Mar - Parc de Salut Mar
    Barcelona, 08003, Spain
  • Area Sanitaria De Ferrol - Hospital Arquitecto Marcide
    Ferrol, 15405, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, 28222, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, 30120, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in May 2026, 28 months.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 28 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
Dec 20, 2023
Primary completionActual
May 18, 2026
CompletionActual
May 18, 2026
Results delay requested
Sep 10, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017609
Lead sponsor
Akros Pharma Inc.
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Dec 20, 2023
Primary completion
May 18, 2026
Completion
May 18, 2026
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion